Image from Airtable
IO Biotech filed Ch 7. Gossamer laid off 48%. Two Phase III failures in one week. Here's what nobody's saying: every one of those trials had CRCs running visits the morning the news hit. The hidden tax of biotech failure gets paid by sites that do the right thing when the money runs out.
A coordinator needed to confirm one inclusion criterion before a screening visit.
The protocol referenced another section. That referenced an appendix. The appendix referenced a scanned amendment.
1 question. 4 documents. 30 minutes. Patient waiting the whole time.
#clinicalresearch
Clinical researchers still flip through binders and ctrl‑F huge PDFs to find protocol answers. Our AI tool gives them the right answer in seconds, plus a full audit trail and secure handling of sponsor IP. #wpays
Most of what matters compounds slowly. You do the work on Tuesday, and that work quietly pays you back every day after. The shortcuts look faster. They're not.
Two weeks ago I posted about tier-one vs tier-two sites.
This week CenExel made the case for me.
Five site expansions. Psychedelic dosing rooms. Phase I inpatient units. CNS infrastructure. Specialized infrastructure is the moat. Tier one competes on price.
#clinicalresearch
Image from Airtable
NIH obligated $5.8B through March 20. That's 34% below the same point in FY24.
New awards down 63%.
Independent sites will feel this on a lag: quieter PI conversations in 90 days, narrower top-of-funnel in 6 months.
Flag your NIH-linked protocols now.
April is National Volunteer Month.
Every patient in a clinical trial is a volunteer.
Not a subject. Not a participant ID.
The cost of every visit (parking, time, childcare, side effects) is absorbed by the volunteer.
Every piece of friction in a protocol gets paid for by them.
The FDA just rewrote what counts as evidence three times since late Feb.
Read which sponsors move first, and which of your current relationships are inside the shift.
Image from Airtable
You'll spend $10K on patient recruitment and $15K on new software. But when your lead CRC asks for a raise, you "check the budget." Replacing them costs $50-60K. A $5K tuition benefit costs less than 10% of that.
Image from Airtable
You don't need to have it all figured out by Monday morning. Show up, do the next right thing, trust the rest will follow. That's always been enough.
Image from Airtable
The people who changed your life probably don't know they did. A teacher, a stranger, a friend who checked in. You've been that person for someone too. Even if they never told you.
Advocate Health launching 100,000 drone deliveries per year. Prescriptions, labs, supplies. Straight to patient doorsteps. When sponsors ask "can we deliver IP by drone?" the sites with compliant SOPs for chain-of-custody, temperature monitoring, and receipt verification will win those contracts.
FDA just made single-trial approval the standard.
One pivotal study = one shot.
Sponsors will select sites like they're drafting a championship team. Query rates, resolution times, deviation history. Quality isn't a nice-to-have anymore. It's your business model.
ICON and Advarra just partnered to build a connected site network.
If your site runs Advarra's stack, ICON sees your capacity in real time. No feasibility questionnaires. Your software just became a business development tool.
The question: does your tech stack open doors or quietly close them?
IMA bought Chicago Research Center for its six-bed sleep lab and 50K patient database. That's infrastructure a network can't replicate overnight.
Independent sites: the question is "what can we build that's hard to copy?" That's your moat.
Aldeyra got a Complete Response Letter from FDA for their dry eye drug.
No more trials planned. Sites with this on their forecast just lost a revenue stream.
Pipeline diversification across sponsor types and development phases is risk management, not growth strategy.
#clinicalresearch
Image from Airtable
CROs just got up to 75% faster at generating certain documentation.
When protocols and amendments arrive at machine speed, coordinators still navigating 12 fragmented systems absorb all the pressure. Speed without capacity is just pressure.
#clinicalresearch
Image from Airtable
PE-backed networks are buying the middle class of the site ecosystem. Two site acquisitions:
- PhaseWell bought Chase Medical Research.
- IMA Group bought Chicago Research Center.
Independent sites: specialize or form consortiums. The generalist middle ground is shrinking.
Image from Airtable
CMIC just cut clinical documentation time 75% with AI.
The principle matters more than the tech: map the process, find where time disappears, place the tool there.
I learned this the hard way building a hardware startup - process first, technology second.
Image from Airtable
FDA issued 30 warning letters to telehealth companies selling compounded GLP-1s.
As compounded supply tightens, patients may flow back to site-based clinical trials.
Sites running obesity and cardiometabolic studies: update your recruitment messaging now.
7 open roles per 1 candidate??
383 NIH trials halted, and what the sites keeping their people are doing differently. Quick read in this week's newsletter.
maxoutput.substack.com/publish/post/191949667
CRCs managing studies now manage many different sponsor-mandated platforms.
The tech reducing burden is creating new burden: platform fatigue.
Negotiate a line item for training time. Protect your time.
Image from Airtable
The government canceled $500M in mRNA vaccine research contracts.
This is why sites should diversify their protocol portfolio and negotiate protections for termination‑related workload up front.
For sites, that likely meant urgent IRB updates, rapid patient outreach, and unplanned close out work.
Kyowa Kirin terminated all rocatinlimab studies practically overnight following a safety review of its late stage program.
ICON plc disclosed multi-year revenue overstatements. Stock dropped 40%.
If you run trials managed by ICON: invoice every completed visit today and track A/R weekly.
Biotech VC funding rounds dropped 25% to a 5-year low. 237 rounds, down from 317.
Audit your sponsor mix now.
maxoutput.substack.com/p/the-fda-just-replaced-...
One common victim: independent sites.